| Literature DB >> 29233117 |
Przemysław Zdziarski1, Mariola Paściak2, Klaudia Rogala3, Agnieszka Korzeniowska-Kowal3, Andrzej Gamian3.
Abstract
BACKGROUND: Elizabethkingia miricola is a rare Gram-negative bacterium found in water and clinical specimens. Typical culturing methods often misidentify Elizabethkingia spp. as Flavobacterium or Chryseobacterium. Although diagnosis is based on culturing samples taken from sterile sites, such as blood, a proper identification of this bacterium requires an expertise that goes beyond the capabilities of a typical clinical laboratory. CASEEntities:
Keywords: Elizabethkingia miricola; MALDI-TOF Biotyper; Natural history of disease; Periodontitis; Portal of entry; Superinfection
Mesh:
Substances:
Year: 2017 PMID: 29233117 PMCID: PMC5727958 DOI: 10.1186/s12879-017-2886-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Clinical strains isolated from the patient and identified by MALDI-TOF MS Biotyper system
| Strain | Conditions | Score valuea |
|---|---|---|
|
| Aerobic | 2.346 |
|
| Aerobic | 2.443 |
|
| Aerobic | 2.29 |
|
| Aerobic | 2.2 |
|
| Aerobic | 2.256 |
|
| Aerobic | 2.18 |
|
| Aerobic | 2.171 |
|
| Aerobic | 2.276 |
|
| Aerobic | 1.771 |
|
| Anaerobic | 2.043 |
|
| Anaerobic | 2.194 |
aScore values determined by MALDI Biotyper: < 1.7 – identification not reliable, 1.7–2.0 – probable genus identification, 2.0–2.3 – secure genus identification and probable species identification, > 2.3 – highly probable species identification
Results of antimicrobial susceptibility testing for clinical isolate E. miricola
| Antimicrobiala | MIC (mg/L) | MIC breakpoint (mg/L) | Interpretation | |
| Susceptible ≤ | Resistant > | |||
| Cefepime | ≥32 | 4 | 8 | Resistant |
| Piperacillin | ≥128 | 4 | 16 | Resistant |
| Piperacillin/Tazobactam | ≥128 | 4 | 16 | Resistant |
| Ticarcillin/Clavulanic acid | ≥128 | 8 | 16 | Resistant |
| Ciprofloxacin | ≤0.25 | 0.5 | 1 | Susceptible |
| Levofloxacin | 0.25 | 1 | 2 | Susceptible |
| Meropenem | ≥16 | 2 | 8 | Resistant |
| Gentamicin | 8 | 4 | 4 | Resistant |
| Amikacin | ≥64 | 8 | 16 | Resistant |
| Tobramycin | ≥16 | 4 | 4 | Resistant |
| Colistin | ≥16 | 4 | 4 | Resistant |
| Antimicrobialb | Inhibition diameter (mm) | Zone diameter breakpoint (mm) | Interpretation | |
| Susceptible ≥ | Resistant < | |||
| Ceftazidime | 6 | 17 | 17 | Resistant |
| Cefepime | 12 | 19 | 19 | Resistant |
| Trimethoprim/Sulfamethoxazole | 24 | 16 | 16 | Susceptible |
| Amikacin | 13 | 18 | 15 | Resistant |
| Gentamicin | 14 | 15 | 15 | Resistant |
| Imipenem | 6 | 20 | 17 | Resistant |
| Meropenem | 6 | 24 | 18 | Resistant |
| Levofloxacin | 27 | 20 | 17 | Susceptible |
| Ciprofloxacin | 28 | 25 | 22 | Susceptible |
aAntimicrobial susceptibility testing using Vitek 2 (bioMérieux, Marcy l’Etoile, France), according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines 2016 (http://www.eucast.org). For interpretation, non–species-related (pharmacokinetics/ pharmacodynamics) breakpoints were used except for gentamicin, amikacin, tobramycin and colistin, in which Pseudomonas sp. breakpoints were used
bAntimicrobial susceptibility testing by the disc diffusion method according to 2016 EUCAST guidelines (http://www.eucast.org). For interpretation, non–species-related (pharmacokinetics/ pharmacodynamics) breakpoints were used except for trimethoprim/ sulfamethoxazole, in which Stenotrophomonas maltophilia breakpoints were used, and for gentamicin, amikacin, tobramycin, ciprofloxacin and levofloxacin, in which Pseudomonas sp. breakpoints were used